Potential involvement of MYC- And p53-related pathways in tumorigenesis in human oral squamous cell carcinoma revealed by proteomic analysis

Journal of Proteome Research

Volumn 7, Issue 9, 2008, Pages 3818-3829

  Koehn, Jadranka ^a,b   Krapfenbauer, Kurt ^b   Huber, Susanna ^b   Stein, Elisabeth ^a   Sutter, Walter ^a   Watzinger, Franz ^a   Erovic, Boban M ^a   Thurnher, Dietmar ^a   Schindler, Thomas ^c   Fountoulakis, Michael ^c   Turhani, Dritan ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Novartis Institutes for BioMedical Research Vienna   (Austria)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

MYC; Oral squamous cell carcinoma (oscc); P53; Protein pathway profiling; Proteomics; Systems biology; Two dimensional database

Indexed keywords

BIOLOGICAL MARKER; MITOCHONDRIAL PROTEIN; MYC PROTEIN; PROTEIN P53;

ARTICLE; BLOOD SAMPLING; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; GENE CONTROL; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METASTASIS; MOUTH CARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TWO DIMENSIONAL GEL ELECTROPHORESIS; METABOLISM; MOUTH TUMOR; PATHOLOGY; TUMOR CELL LINE;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; IMMUNOHISTOCHEMISTRY; MOUTH NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 55249106930     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr800077a     Document Type: Article

References (67)

1. Fearlay, J.; Bray, F.; Pisani, P.; Parkin, D. M. Cancer inidence, mortality and prevalence worldwide, version 1.0; IARC Cancer Base No. 5; IARC Press: Lyon, 2001.
2. Wulfkuhle, J. D.; McLean, K. C; Paweletz, C. P.; Sgroi, D. C; Track, B. J.; Steeg, P. S.; Petricoin, E. F., 3rd. New approaches to proteomic analysis of breast cancer. Proteomics 2001, 1 (10), 1205-15.
3. Xiao, X.; Liu, D.; Tang, Y.; Guo, F.; Xia, L.; Liu, J.; He, D. Development of proteomic patterns for detecting lung cancer. Dis. Markers 2003, 19 (1), 33-9.
4. Peyrl, A.; Krapfenbauer, K.; Slavc, I.; Yang, J. W.; Strobel, T.; Lubec, G. Protein profiles of medulloblastoma cell lines DAOY and D283: identification of tumor-related proteins and principles. Proteomics 2003, 3 (9), 1781-800.
5. Trog, D.; Fountoulakis, M.; Friedlein, A.; Golubnitschaja, O. Is current therapy of malignant gliomas beneficial for patients? Proteomics evidence of shifts in glioma cells expression patterns under clinically relevant treatment conditions. Proteomics 2006, 6 (9), 2924-30.
6. Bichsel, V. E.; Liotta, L. A.; Petricoin, E. F. 3rd, Cancer proteomics: from biomarker discovery to signal pathway profiling. Cancer J. 2001, 7 (1), 69-78.
7. Fountoulakis, M. Proteomics: current technologies and applications in neurological disorders and toxicology. Amino Acids 2001, 21 (4), 363-81.
8. Fountoulakis, M. Application of proteomics technologies in the investigation of the brain. Mass Spectrom. Rev. 2004, 23 (4), 231-58.
9. Koike, H.; Uzawa, K.; Nakashima, D.; Shimada, K.; Kato, Y.; Higo, M.; Kouzu, Y.; Endo, Y.; Kasamatsu, A.; Tanzawa, H. Identification of differentially expressed proteins in oral squamous cell carcinoma using a global proteomic approach. Int. J. Oncol. 2005, 27 (1), 59-67.
10. Brennan, J. A.; Sidransky, D. Molecular staging of head and neck squamous carcinoma. Cancer Metastasis Rev. 1996, 15 (1), 3-10.
11. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-54.
12. Krapfenbauer, K.; Fountoulakis, M.; Lubec, G, A rat brain protein expression map including cytosolic and enriched mitochondrial and microsomal fractions. Electrophoresis 2003, 24 (11), 1847-70.
13. Fountoulakis, M.; Langen, H. Identification of proteins by matrix- assisted laser desorption ionization-mass spectrometry following in-gel digestion in low-salt, nonvolatile buffer and simplified peptide recovery. Anal, Biochem. 1997, 250 (2), 153-6.
14. Fountoulakis, M.; Gasser, R. Proteomic analysis of the cell envelope fraction of Escherichia coli. Amino Acids 2003, 24 (1-2), 19-41.
15. Garbis, S.; Lubec, G.; Fountoulakis, M. Limitations of current proteomics technologies. J. Chromatogr. A 2005, 1077 (1), 1-18.
16. Berndt, P.; Hobohm, U.; Langen, H. Reliable automatic protein identification from matrix-assisted laser desorption/ionization mass spectrometric peptide fingerprints. Electrophoresis 1999, 20 (18), 3521-6.
17. Monigatti, F.; Berndt, P. Algorithm for accurate similarity measurements of peptide mass fingerprints and its application. J. Am. Soc. Mass Spectrom. 2005, 16 (1), 13-21.
18. Chomczynski, P.; Mackey, K. Short technical reports. Modification of the TRI reagent procedure for isolation of RNA from polysaccharide-and proteoglycan-rich sources. Biotechniques 1995, 19 (6), 942-5.
19. Pfaffl, M. W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29 (9), e45.
20. Turhani, D.; Krapfenbauer, K.; Thurnher, D.; Langen, H.; Fountoulakis, M. Identification of differentially expressed, tumor- associated proteins in oral squamous cell carcinoma by proteomic analysis. Electrophoresis 2006, 27 (7), 1417-23.
21. Tamir, Y.; Bengal, E. p53 protein is activated during muscle differentiation and participates with MyoD in the transcription of muscle creatine kinase gene. Oncogene 1998, 17 (3), 347-56.
22. Poeta, M. L.; Manola, J.; Goldwasser, M. A.; Forastiere, A.; Benoit, N.; Califano, J. A.; Ridge, J. A.; Goodwin, J.; Kenady, D.; Saunders, J.; Westra, W.; Sidransky, D.; Koch, W. M. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 2007, 357 (25), 2552-61.
23. Erber, R.; Conradt, C; Homann, N.; Enders, C.; Finckh, M.; Dietz, A.; Weidauer, H.; Bosch, F. X. TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer. Oncogene 1998, 16 (13), 1671-9.
24. Brennan, J. A.; Boyle, J. O.; Koch, W. M.; Goodman, S. N.; Hruban, R. H.; Eby, Y. J.; Couch, M. J.; Forastiere, A. A.; Sidransky, D. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 1995, 332 (11), 712-7.
25. Ahomadegbe, J. C; Barrois, M.; Fogel, S.; LeBihan, M. L.; DoucRasy, S.; Duvillard, P.; Armand, J. P.; Riou, G. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 1995, 10 (6), 1217-27.
26. Xu, L.; Chen, Y. T.; Huvos, A. G.; Zlotolow, I. M.; Rettig, W. J.; Old, L. J.; Garin-Chesa, P. Overexpression of p53 protein in squamous cell carcinomas of head and neck without apparent gene mutations. Diagn. Mol. Pathol. 1994, 3 (2), 83-92.
27. Rawal, R. M.; Patel, P. S.; Vyas, R. K.; Sainger, R. N.; Shah, M. H.; Peshavariya, H. M.; Patel, D. D.; Bhatavdekar, J. M. Role of pretherapeutic biomarkers in predicting postoperative radiotherapy response in patients with advanced squamous cell carcinoma. Int. J. Radiat. Biol. 2001, 77 (11), 1141-6.
28. Hippo, Y.; Yashiro, M.; Ishii, M.; Taniguchi, H.; Tsutsumi, S.; Hirakawa, K.; Kodama, T.; Aburatani, H. Differential gene expression profiles of scirrhous gastric cancer cells with high metastatic potential to peritoneum or lymph nodes. Cancer Res. 2001, 61 (3), 889-95.
29. Aitken, A. 14-3-3 proteins on the MAP. Trends Biochem. Sci. 1995, 20 (3), 95-7.
30. Fu, H.; Subramanian, R. R.; Masters, S. C. 14-3-3 proteins: structure, function, and regulation. Annu. Rev. Pharmacol. Toxicol. 2000, 40, 617-47.
31. Wang, W.; Shakes, D. C. Molecular evolution of the 14-3-3 protein family. J Mol Evol 1996, 43 (4), 384-98.
32. Yang, H. Y.; Wen, Y. Y.; Chen, C. H.; Lozano, G.; Lee, M. H. 14-3-3 sigma positively regulates p53 and suppresses tumor growth. Mol. Cell. Biol. 2003, 23 (20), 7096-107.
33. Erovic, B. M.; Pelzmann, M.; Grasl, M.; Pammer, J.; Kornek, G.; Brannath, W.; Selzer, E.; Thurnher, D. Mcl-1, vascular endothelial growth factor-R2, and 14-3-3sigma expression might predict primary response against radiotherapy and chemotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. Clin. Cancer Res. 2005, 11 (24 Pt 1), 8632-6.
34. Matta, A.; Desouza, L. V.; Shukla, N. K.; Gupta, S. D.; Ralhan, R.; Siu, K. W. Prognostic Significance of Head-and-Neck Cancer Biomarkers Previously Discovered and Identified Using 1TRAQ- Labeling and Multidimensional Liquid Chromatography-Tandem Mass Spectrometry.J. Proteome Res. 2008, 7 (5), 2078-2087.
35. Ralhan, R.; Desouza, L. V.; Matta, A.; Chandra Tripathi, S.; Ghanny, S.; Datta Gupta, S.; Bahadur, S.; Siu, K. W. Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ-labeling and multidimensional liquid chromatography and tandem mass spectrometry. Mol. Cell. Proteomics 2008, 7(6), 1162-73.
36. Sivak, L. E.; Tai, K. F.; Smith, R. S.; Dillon, P. A.; Brodeur, G. M.; Carroll, W. L. Autoregulation of the human N-myc oncogene is disrupted in amplified but not single-copy neuroblastoma cell lines. Oncogene 1997, 15 (16), 1937-46.
37. Godfried, M. B.; Veenstra, M.; v Sluis, P.; Boon, K.; v Asperen, R.; Hermus, M. C; v Schaik, B. D.; Voute, T. P.; Schwab, M.; Versteeg, R.; Caron, H. N. The N-myc and c-myc downstream pathways include the chromosome 17q genes nm23-Hl and nm23-H2. Oncogene 2002, 21 (13), 2097-101.
38. Hiyama, E.; Hiyama, K.; Yamaoka, H.; Sueda, T.; Reynolds, C. P.; Yokoyama, T. Expression profiling of favorable and unfavorable neuroblastomas. Pediatr. Surg. Int. 2004, 20 (1), 33-8.
39. Kato, K.; Katoh-Semba, R.; Takeuchi, I. K.; Ito, H.; Kamei, K. Responses of heat shock proteins hsp27, alphaB-Crystallin, and hsp70 in rat brain after kainic acid-induced seizure activity. J. Neurochem. 1999, 73 (1), 229-36.
40. Krapfenbauer, K.; Berger, M.; Lubec, G.; Fountoulakis, M. Changes in the brain protein levels following administration of kainic acid. Electrophoresis 2001, 22 (10), 2086-91.
41. van de Klundert, J. A.; den Turk, E.; Borman, A. H.; van der Meide, P. H.; Bosch, L. Isolation and characterization of a mocimycin resistant mutant of Escherichia coli with an altered elongation factor EF-Tu. FEBS Lett. 1977, 81 (2), 303-7.
42. Diffee, G. M.; Kalfas, K.; Al-Majid, S.; McCarthy, D. O. Altered expression of skeletal muscle myosin isoforms in cancer cachexia. Am. J. Physiol. Cell. Physiol. 2002, 283 (5), C1376-82.
43. He, Q. Y.; Chen, J.; Kung, H. F.; Yuen, A. P.; Chiu, J. F. Identification of tumor-associated proteins in oral tongue squamous cell carcinoma by proteomics. Proteomics 2004, 4 (1), 271-8.
44. Nozoe, T.; Korenaga, D.; Futatsugi, M.; Saeki, H.; Maehara, Y.; Sugimachi, K. Immunohistochemical expression of C-reactive protein in squamous cell carcinoma of the esophagus-significance as a tumor marker. Cancer Lett. 2003, 192 (1), 89-95.
45. Chen, Z.; Malhotra, P. S.; Thomas, G. R.; Ondrey, F. G.; Duffey, D. C; Smith, C. W.; Enamorado, I.; Yeh, N. T.; Kroog, G. S.; Rudy, S.; McCullagh, L.; Mousa, S.; Quezado, M.; Herscher, L. L.; Van Waes, C. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin. Cancer Res. 1999, 5 (6), 1369-79.
46. Salonen, E. M.; Vartio, T.; Hedman, K.; Vaheri, A. Binding of fibronectin by the acute phase reactant C-reactive protein. J. Biol. Chem. 1984, 259 (3), 1496-501.
47. Erovic, B. M.; Pelzmann, M.; Turhani, D.; Pammer, J.; Niederberger, V.; Neuchrist, C; Grasl, M.; Thurnher, D. Differential expression pattern of cyclooxygenase-1 and-2 in head and neck squamous cell carcinoma. Acta Otolaryngol. 2003, 123 (8), 950-3.
48. Thurnher, D.; Turhani, D.; Pelzmann, M.; Wannemacher, B.; Knerer, B.; Formanek, M.; Wacheck, V.; Selzer, E. Betulinic acid: a new cytotoxic compound against malignant head and neck cancer cells. Head Neck 2003, 25 (9), 732-40.
49. Thurnher, D.; Bakroeva, M.; Schutz, G.; Pelzmann, M.; Formanek, M.; Knerer, B.; Kornfehl, J. Non-steroidal anti-inflammatory drugs induce apoptosis in head and neck cancer cell lines. Acta Otolaryngol. 2001, 121 (8), 957-62.
50. Thurnher, D.; Kornfehl, J.; Burian, M.; Gedlicka, C; Selzer, E.; Quint, C; Neuchrist, C; Kornek, G. V. Ifosfamide and mitoxantrone in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Anticancer Drugs 2001, 12 (3), 205-8.
51. Garcia Pedrero, J. M.; Fernandez, M. P.; Morgan, R. O.; Herrero Zapatero, A.; Gonzalez, M. V.; Suarez Nieto, C.; Rodrigo, J. P. Annexin Al down-regulation in head and neck cancer is associated with epithelial differentiation status. Am. J. Pathol. 2004, 164 (1), 73-9.
52. Chetcuti, A.; Margan, S. H.; Russell, P.; Mann, S.; Millar, D. S.; Clark, S. J.; Rogers, J.; Handelsman, D. J.; Dong, Q. Loss of annexin II heavy and light chains in prostate cancer and its precursors. Cancer Res. 2001, 61 (17), 6331-4.
53. Feldman, A. L.; Espina, V.; Petricoin, E. F., 3rd; Liotta, L. A.; Rosenblatt, K. P. Use of proteomic patterns to screen for gastrointestinal malignancies. Surgery 2004, 135 (3), 243-7.
54. Paweletz, C. P.; Ornstein, D. K.; Roth, M. J.; Bichsel, V. E.; Gillespie, J. W.; Calvert, V. S.; Vocke, C. D.; Hewitt, S. M.; Duray, P. H.; Herring, J.; Wang, Q. H.; Hu, N.; Linehan, W. M.; Taylor, P. R.; Liotta, L. A.; Emmert-Buck, M. R.; Petricoin, E. F. 3rd, Loss of annexin 1 correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. Cancer Res. 2000, 60 (22), 6293-7.
55. Somay, C; Grunt, T. W.; Mannhalter, C; Dittrich, C. Relationship of myc protein expression to the phenotype and to the growth potential of HOC-7 ovarian cancer cells. Br. J. Cancer 1992, 66 (1), 93-8.
56. Pomerantz, J.; Schreiber-Agus, N.; Liegeois, N. J.; Silverman, A.; Alland, L.; Chin, L.; Potes, J.; Chen, K.; Orlow, I.; Lee, H. W.; Cordon-Cardo, C; DePinho, R. A. The Ink4a tumor suppressor gene product, pl9Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998, 92 (6), 713-23.
57. Sherr, C. J. Tumor surveillance via the ARF-p53 pathway. Genes Dev. 1998, 12 (19), 2984-91.
58. Sakai, E.; Rikimaru, K.; Ueda, M.; Matsumoto, Y.; Ishii, N.; Enomoto, S.; Yamamoto, H.; Tsuchida, N. The p53 tumor-suppressor gene and ras oncogene mutations in oral squamous- cell carcinoma. Int. J. Cancer 1992, 52 (6), 867-72.
59. Kusama, K.; Okutsu, S.; Takeda, A.; Himiya, T.; Kojima, A.; Kidokoro, Y.; Chu, L.; Iwanari, S.; Kudo, I.; Moro, I. p53 gene alterations and p53 protein in oral epithelial dysplasia and squamous cell carcinoma. J. Pathol. 1996, 178 (4), 415-21.
60. De Rosa, G.; Staibano, S.; Barra, E.; Donofrio, V.; Salvatore, G.; Vessecchia, G.; Boscaino, A. p53 protein in aggressive and non- aggressive basal cell carcinoma. J. Cutan. Pathol. 1993, 20 (5), 429- 34.
61. Zhang, H.; Ping, X. L.; Lee, P. K.; Wu, X. L.; Yao, Y. J.; Zhang, M. J.; Silvers, D. N.; Ratner, D.; Malhotra, R.; Peacocke, M.; Tsou, H. C. Role of PTCH and p53 genes in early-onset basal cell carcinoma. Am. J. Pathol. 2001, 158 (2), 381-5.
62. Xie, J.; Murone, M.; Luoh, S. M.; Ryan, A.; Gu, Q.; Zhang, C; Bonifas, J. M.; Lam, C. W.; Hynes, M.; Goddard, A.; Rosenthal, A.; Epstein, E. H., Jr.; de Sauvage, F. J. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 1998, 391 (6662), 90-2.
63. Nishimaki, H.; Kasai, K.; Kozaki, K.; Takeo, T.; Ikeda, H.; Saga, S.; Nitta, M.; Itoh, G. A role of activated Sonic hedgehog signaling for the cellular proliferation of oral squamous cell carcinoma cell line. Biochem. Biophys. Res. Commun. 2004, 314 (2), 313-20.
64. Boukamp, P. Non-melanoma skin cancer: what drives tumor development and progression. Carcinogenesis 2005, 26 (10), 1657- 67.
65. Field, J. K. Oncogenes and tumour-suppressor genes in squamous cell carcinoma of the head and neck. Eur. J. Cancer B: Oral Oncol. 1992, 28B (1), 67-76.
66. Menssen, A.; Hermeking, H. Characterization of the c-MYC- regulated transcriptome by SAGE: identification and analysis of c-MYC target genes. Proc. Natl. Acad. Sci. U.SA. 2002, 99 (9), 6274- 9.
67. Crook, T.; Wrede, D.; Tidy, J.; Scholefield, I.; Crawford, L.; Vousden, K. H. Status of c-myc, p53 and retinoblastoma genes in human papillomavirus positive and negative squamous cell carcinomas of the anus. Oncogene 1991, 6 (7), 1251-7.